And what was the primary outcome of the trial? And can you walk us through some of the key findings and perhaps some of the additional secondary and exploratory outcomes too?

Yeah.

So the primary endpoint was the time from remission to relapse.

We had a median follow-up time of 2.8 years.

And we found that the placebo group relapsed after a median of less than six months.

Whereas the rituximab group was still, we didn't reach the median remission time during follow-up.

So they were still in remission.

You've given them a six month dose, but how long do you think we should be treating these individuals? I've got a couple of patients who I have kept on, who have steroid responsive, but frequently relapsing minimal change disease who I'm treating with rituximab, but What really is the evidence for how long we should be treating these patients for?